Collaboration between specific anti-tumor immunity and chemotherapeutic agents

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Melphalan is a chemotherapeutic agent used in cancer treatment.
• Tumor recurrence after chemotherapy is a significant clinical challenge.
• The role of the immune system in chemotherapy response is not fully understood.

Purpose of the Study:

• To investigate the efficacy of melphalan in a syngeneic mouse model of mammary adenocarcinoma.
• To explore the impact of immune stimulation on melphalan treatment outcomes.
• To elucidate mechanisms of chemoresistance in vivo.

Main Methods:

• Treatment of DBA/2J mice with melphalan for T1699 mammary adenocarcinoma.
• Immune stimulation using bacterial lipopolysaccharide (LPS) or phytohemagglutinin (PHA) before melphalan therapy.
• In vitro assessment of drug susceptibility and cytotoxicity of tumor cells with immune effector cells.

Main Results:

• Single-dose melphalan achieved 65% tumor regression, but 85% of these recurred.
• Immune stimulation with LPS or PHA significantly increased regression and permanent cures.
• A melphalan-resistant tumor subline (TR2) showed increased drug susceptibility after exposure to immune effector cells in vitro.

Conclusions:

• Immune stimulation can enhance the efficacy of melphalan chemotherapy and increase cure rates.
• In vivo tumor resistance to chemotherapy may involve mechanisms beyond intrinsic drug resistance of tumor cells.
• Immune effector cells can increase tumor cell susceptibility to melphalan, suggesting a collaborative cytotoxicity mechanism.